2024 Latin America Conference on Lung Cancer (LALCA) - Posters-PP01.05: Comparison of Progression-Free Survival (PFS) in Patients With Non-Small Cell Lung Cancer (NSCLC) According to Their Actionable Mutations

PP01.05: Comparison of Progression-Free Survival (PFS) in Patients With Non-Small Cell Lung Cancer (NSCLC) According to Their Actionable Mutations

Back to course

Pdf Summary

The study investigates the progression-free survival (PFS) of patients with non-small cell lung cancer (NSCLC) and different actionable mutations, focusing on the Mexican population. Utilizing next-generation sequencing (NGS), researchers identified prevalent mutations in genes like EGFR, KRAS, ALK, and MET. The study involved 64 NSCLC patients, primarily with adenocarcinoma, and compared their PFS using Kaplan-Meier analysis and multivariate linear regression.<br /><br />Key findings include that those with EGFR-sensitive mutations had a significantly lower risk of disease progression with a hazard ratio (HR) of 0.607, indicating better outcomes compared to other mutations such as ALK, RET, BRAF, KRAS, and ROS1. Notably, the ALK mutation group exhibited the poorest prognosis. Immunotherapy, received by 42.19% of patients, was associated with a 13% lower risk of progression, albeit not statistically significant.<br /><br />Smoking status was a negative prognostic factor, with smokers showing a higher HR of 1.573 compared to non-smokers. Interestingly, patients with a family history of cancer had a trend towards faster progression, indicating potential hereditary influences, though not statistically significant (HR 0.703). Conversely, female gender and the presence of EGFR mutations were linked to better prognosis, differing from other studies.<br /><br />Concluding, the study underscores EGFR mutations and female gender as positive prognostic indicators in the Mexican cohort, while suggesting family history may accelerate progression. The findings emphasize the necessity for further studies to validate these observations and improve bespoke treatments for NSCLC patients. This research provides valuable insights into the molecular epidemiology of NSCLC in Mexican patients and raises considerations for tailored treatment strategies based on genetic profiles.

Asset Subtitle

Iván Romarico González-Espinoza

Keywords

progression-free survival

non-small cell lung cancer

Mexican population

next-generation sequencing

EGFR mutations

Kaplan-Meier analysis

immunotherapy

smoking status

family history

molecular epidemiology